Skip to main content
Genesystem Co., Ltd logo

Genesystem Co., Ltd — Investor Relations & Filings

Ticker · 363250 ISIN · KR7363250002 KO Manufacturing
Open in API
Filings indexed 173 across all filing types
Latest filing 2021-05-12 Capital/Financing Update
Country KR South Korea
Listing KO 363250

About Genesystem Co., Ltd

https://genesystem.co.kr/

Genesystem Co., Ltd. is a biotechnology engineering company specializing in the development and commercialization of molecular diagnostic solutions for point-of-care testing (POCT) applications. The company focuses on making Polymerase Chain Reaction (PCR) testing faster, simpler, and more accessible for on-site use. It develops and markets rapid PCR platforms, proprietary reagents, and biochip-based products. Key technologies include ultra-fast PCR, miniaturized heating modules, and multiplex biochip systems that enable precise and convenient analysis. Genesystem's solutions serve various markets, including human healthcare for pathogen detection and food safety for identifying foodborne pathogens and meat authentication.

Recent filings

Filing Released Lang Actions
[기재정정]증권신고서(지분증권) (2021.05)
Capital/Financing Update Classification · 95% confidence The document is a 'Securities Registration Statement' (증권신고서) filed by GeneSystem (주식회사 진시스템) in South Korea. It contains detailed information regarding the company's public offering, including risk factors, business descriptions, and financial information, which is characteristic of a registration statement filed for an IPO or capital raise. In the context of the provided filing categories, this document serves as a formal regulatory filing for a securities offering, which aligns with the 'Regulatory Filings' (RNS) category as it is a primary disclosure document for public market entry.
2021-05-12 Korean
[기재정정]투자설명서
M&A Activity Classification · 95% confidence The document is a '투자설명서' (Investment Prospectus) which is a formal regulatory document filed by a company (JinSystem) in preparation for a public offering or listing. It contains detailed information about the company, risk factors, and offering terms. In the context of financial filings, a prospectus is a primary disclosure document for securities issuance, which falls under the category of Proxy Solicitation & Information Statement (PSI) or Regulatory Filings (RNS). Given the specific nature of the document as a formal offering document for investors, it is classified as a Proxy Solicitation & Information Statement (PSI) as it serves to inform potential shareholders and solicit investment.
2021-05-12 Korean
[발행조건확정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 95% confidence The document is a '증권신고서(지분증권) 정정신고서' (Amendment to Securities Registration Statement) filed with the Financial Services Commission (금융위원회) in South Korea. It details the finalization of the public offering price (공모가액 확정) for Genesystem Co., Ltd. (주식회사 진시스템). This type of filing is a regulatory document related to the issuance of shares and capital changes, which falls under the 'Share Issue/Capital Change' category in the provided schema.
2021-05-11 Korean
[기재정정]투자설명서
Capital/Financing Update Classification · 98% confidence The document is a 'Correction Report' (정정신고서) for an 'Investment Prospectus' (투자설명서) filed by Jin System Co., Ltd. in South Korea. It details changes to the public offering price (from a range of 16,000-20,000 KRW to a fixed 20,000 KRW) and related financial figures following the book-building process. In the context of Korean regulatory filings (DART), this is a formal amendment to a securities registration statement/prospectus. Given the provided categories, this document relates to capital raising and financing activities, making 'CAP' (Capital/Financing Update) the most accurate classification.
2021-05-11 Korean
투자설명서
Capital/Financing Update Classification · 98% confidence The document is a '투자설명서' (Investment Prospectus) for a company named '주식회사 진시스템' (GeneSystem Co., Ltd.). It contains detailed information regarding a public offering, including offering price, subscription period, risk factors (business and company-specific), and financial disclosures. This document is a formal regulatory filing required for an IPO or public offering of securities, which falls under the category of Proxy Solicitation & Information Statement (PSI) or a general regulatory filing. Given the specific nature of the document as a prospectus for investors, 'PSI' is the most accurate classification within the provided schema.
2021-05-06 Korean
[기재정정]증권신고서(지분증권) (2021.05)
Capital/Financing Update Classification · 98% confidence The document is a 'Correction Report' (정정신고서) for a Securities Registration Statement (증권신고서) filed by GeneSystem (주식회사 진시스템). It details specific amendments to the initial registration statement regarding share issuance, offering terms, and business descriptions. In the context of Korean financial filings (DART system), a 'Securities Registration Statement' and its subsequent amendments are classified under capital raising and financing activities. Since this is a formal regulatory filing for a public offering of shares, it falls under the 'Capital/Financing Update' category.
2021-04-29 Korean

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.